Regulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) in a research note issued to investors on Sunday. The firm set a "sell" rating on the biopharmaceutical company's stock.

Several other brokerages have also commented on RGLS. Leerink Partners restated a "market perform" rating and set a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Wells Fargo & Company restated an "equal weight" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Canaccord Genuity Group reiterated a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, Jones Trading reiterated a "hold" rating and issued a $7.00 target price (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Stock Up 0.3%

Shares of RGLS opened at $7.87 on Friday. The company's fifty day moving average is $3.41 and its 200-day moving average is $2.10. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.20. The firm has a market cap of $544.87 million, a price-to-earnings ratio of -7.36 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14. As a group, research analysts predict that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RGLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Regulus Therapeutics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 1,644 shares during the last quarter. PEAK6 LLC acquired a new stake in Regulus Therapeutics in the 4th quarter worth $95,000. Oppenheimer & Co. Inc. acquired a new stake in Regulus Therapeutics in the 1st quarter worth $96,000. Velan Capital Investment Management LP acquired a new stake in Regulus Therapeutics in the 4th quarter worth $111,000. Finally, AQR Capital Management LLC acquired a new stake in Regulus Therapeutics in the 1st quarter worth $120,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.